Listed

Kiora Pharmaceuticals Inc: Form 10-K for the period ended Dec 31, 2017

Filed with the SEC on Mar 2, 2018 and accepted by EDGAR at Mar 2, 2018, 16:18 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2017-01-01 to 2017-12-31$10.3mus-gaap:ResearchAndDevelopmentExpense
Interest expense12 months2017-01-01 to 2017-12-31$1.2kus-gaap:InterestExpense
Income tax12 months2017-01-01 to 2017-12-31−$1.3mus-gaap:IncomeTaxExpenseBenefit
Operating cash flow12 months2017-01-01 to 2017-12-31−$6.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2017-01-01 to 2017-12-31$37.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2017-12-31$7.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-12-31$8.5mus-gaap:AssetsCurrent
Total assetsAt period end2017-12-31$14.3mus-gaap:Assets
Current liabilitiesAt period end2017-12-31$14.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-12-31$16.2mus-gaap:Liabilities
Shareholders' equityAt period end2017-12-31−$1.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-18-012542. Last ingested by Listed: Nov 12, 2026, 17:43 ET. Listed shows no prices and gives no investment advice.